John Strisower, CEO of PathoLase, noted: “Approximately 900 million people around the world suffer from toenail fungus, including millions in Australia and New Zealand. We’re very much looking forward to making PinPointe FootLaser available to practitioners in both countries, offering them an excellent opportunity for providing a unique and valuable service to their patients.”
